Fahrettin Kucukay1, Osman Melih Topcuoglu2, Ayhan Alpar3, Çetin Murat Altay4, Murat Bulent Kucukay5, Nilgun Isiksalan Ozbulbul6. 1. Department of Interventional Radiology, Faculty of Medicine, Osmangazi University, Buyukdere mah. Meşelik kampusu, 22480, Eskisehir, Turkey. fkucukay@hotmail.com. 2. Department of Interventional Radiology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. 3. Department of Radiology, Sancaktepe Bolge Hastanesi, Istanbul, Turkey. 4. Department of Interventional Radiology, Keciören Research and Training Hospital, Ankara, Turkey. 5. Department of Internal Medicine, Ozel Lokman Hekim Hospital, Ankara, Turkey. 6. Department of Thoracic Radiology, Faculty of Medicine, Osmangazi University, Eskisehir, Turkey.
Abstract
PURPOSE: To investigate the safety, efficacy and long-term results of bronchial artery embolization with microsphere particles (Embosphere® Microspheres, BioSphere Medical, Rockland, MA) 700-900 µm in size for massive hemoptysis. METHODS: One hundred and seventy-four patients (94 female, 80 male; mean age 39.4 ± 5.7) who had bronchial artery embolization for massive hemoptysis between January 2010 and October 2015 were incorporated in the study. Patients had hemoptysis with a mean volume of 525 ± 150 mL (median 500 mL, range 300-1200 mL) over a 24-h period. Underlying pathologies included bronchial artery hypertrophy due to bronchiectasis (56.3% [98/174]), lung cancer (29.9% [52/174]), tuberculosis (10.3% [18/174]) and the rest remained idiopathic (3.4% [6/174]). Mean bronchial artery diameter before the intervention was 3.8 ± 1.5 mm (median 4 mm, range 3.1-7.5 mm). Median follow-up period was 56 months (range 10-82 months). Primary objectives were the technical and clinical success. RESULTS: Technical success was 100%. Clinical success for preventing massive hemoptysis was 91.9% (160/174). There was no procedure-related mortality or morbidities. Minor complications such as chest pain were observed in nine patients (5.0%). Recurrent hemoptysis (8.1%) was observed within 6 months in 14 patients, ten of whom were treated with a second embolization session and the remaining four with a total of three embolization sessions. CONCLUSION: Bronchial artery embolization for massive hemoptysis with Embosphere particles 700-900 µm in size is a safe and effective method with high technical and clinical success rates. Long-term results are excellent.
PURPOSE: To investigate the safety, efficacy and long-term results of bronchial artery embolization with microsphere particles (Embosphere® Microspheres, BioSphere Medical, Rockland, MA) 700-900 µm in size for massive hemoptysis. METHODS: One hundred and seventy-four patients (94 female, 80 male; mean age 39.4 ± 5.7) who had bronchial artery embolization for massive hemoptysis between January 2010 and October 2015 were incorporated in the study. Patients had hemoptysis with a mean volume of 525 ± 150 mL (median 500 mL, range 300-1200 mL) over a 24-h period. Underlying pathologies included bronchial artery hypertrophy due to bronchiectasis (56.3% [98/174]), lung cancer (29.9% [52/174]), tuberculosis (10.3% [18/174]) and the rest remained idiopathic (3.4% [6/174]). Mean bronchial artery diameter before the intervention was 3.8 ± 1.5 mm (median 4 mm, range 3.1-7.5 mm). Median follow-up period was 56 months (range 10-82 months). Primary objectives were the technical and clinical success. RESULTS: Technical success was 100%. Clinical success for preventing massive hemoptysis was 91.9% (160/174). There was no procedure-related mortality or morbidities. Minor complications such as chest pain were observed in nine patients (5.0%). Recurrent hemoptysis (8.1%) was observed within 6 months in 14 patients, ten of whom were treated with a second embolization session and the remaining four with a total of three embolization sessions. CONCLUSION: Bronchial artery embolization for massive hemoptysis with Embosphere particles 700-900 µm in size is a safe and effective method with high technical and clinical success rates. Long-term results are excellent.
Authors: Joachim Kettenbach; Harald Ittrich; Jean Yves Gaubert; Bernhard Gebauer; Jan Albert Vos Journal: Cardiovasc Intervent Radiol Date: 2022-04-08 Impact factor: 2.740
Authors: Cyrus W Beh; Yingli Fu; Clifford R Weiss; Charles Hu; Aravind Arepally; Hai-Quan Mao; Tza-Huei Wang; Dara L Kraitchman Journal: Lab Chip Date: 2020-09-01 Impact factor: 6.799